Australia at the heart of transformational cancer vaccine breakthrough
An Australian-led phase 3 clinical trial for a world-first cancer vaccine demonstrated a 42 percent reduction in the risk of melanoma recurrence and death.
An Australian-led phase 3 clinical trial for a world-first cancer vaccine demonstrated a 42 percent reduction in the risk of melanoma recurrence and death.